RayzeBio develops novel peptide mimetic binders to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter.

Register for Details

For more details on financing and valuation of private companies similar to RayzeBio before its M&A, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about RayzeBio

To invest in RayzeBio pre-IPO

Can you invest in RayzeBio pre-IPO?

You can no longer invest in RayzeBio with Forge. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of RayzeBio before it goes public?

You can no longer sell shares of RayzeBio on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my RayzeBio shares?

Forge can no longer determine the value of RayzeBio shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is RayzeBio a publicly traded company?

RayzeBio became a public company following its M&A on 12/26/2023 and is now a publicly traded company.

To learn more about RayzeBio potential IPO

Will RayzeBio go IPO?

RayzeBio became a public company following its M&A on 12/26/2023.

What is RayzeBio’s IPO price?

The IPO price of RayzeBio is not currently available.

When was RayzeBio founded?

RayzeBio was founded in 2020.

What is RayzeBio funding to date?

RayzeBio has raised $795.51MM to date.

Who are RayzeBio’s major investors?

Venrock
Perceptive Advisors
Sands Capital Ventures
OrbiMed Advisors
Versant Ventures
Redmile Group
Ally Bridge Group
TCG
Samsara Biocapital
Sofinnova Investments
Soleus Capital
venBio
Viking
Vivo Capital

RayzeBio Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
09/13/2022 Series D $159.75MM $xx.xx $599.64MM Viking Global Investors, Sofinnova Investments, Wellington Management, Ally Bridge Group, Sands Capital, Laurion Capital Management, Soleus Capital
Price per Share
$xx.xx
Shares Outstanding
63,972,982
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Viking Global Investors, Sofinnova Investments, Wellington Management, Ally Bridge Group, Sands Capital, Laurion Capital Management, Soleus Capital
06/15/2021 Series C $99.63MM $xx.xx $651.39MM Venrock Healthcare Capital Partners, Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, CG X, venBio Partners, Versant Ventures, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments
Price per Share
$xx.xx
Shares Outstanding
23,999,996
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Venrock Healthcare Capital Partners, Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, CG X, venBio Partners, Versant Ventures, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments
12/08/2020 Series B $96.86MM $xx.xx $237.83MM Venrock Healthcare Capital Partners, OrbiMed, Redmile Group, Viking Global Investors, Logos Capital, Cormorant Asset Management, LifeSci Venture Partners, Alexandria Venture Investments, venBio Partners, Versant Ventures, Samsara BioCapital
Price per Share
$xx.xx
Shares Outstanding
46,666,672
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Venrock Healthcare Capital Partners, OrbiMed, Redmile Group, Viking Global Investors, Logos Capital, Cormorant Asset Management, LifeSci Venture Partners, Alexandria Venture Investments, venBio Partners, Versant Ventures, Samsara BioCapital
10/14/2020 Series A $41.51MM $xx.xx $55.35MM venBio Partners, Versant Ventures, Samsara BioCapital
Price per Share
$xx.xx
Shares Outstanding
45,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
venBio Partners, Versant Ventures, Samsara BioCapital
Updated on: Nov 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.